SCRS Expands Relationship with Acurian
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, announced an expanded relationship with Acurian Inc., a full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD.
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, announced an expanded relationship with Acurian Inc., a full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD.
In this expansion, Acurian support an increased number of member programs. These include the initiation of a Site Advocacy Group (SAG) focused on global patient recruitment and sponsor both the 2015 SCRS Eagle Award and Site Patient Recruitment Innovation Award (SPRIA). Acurian also will continue as a Global Impact Partner and sponsor of 2015 Good Business Practices and Good Clinical Practices webinars.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
